- Clinical Experience
- Rheumatology
- Pulmonology
- Ophthalmology
- Nephrology
- Neurology
- Proposed MOA
- Dosing & Duration
- Safety Data
- Acthar Patient Support
- Resources & Videos
Acthar Patient Support is available. Learn more.
Baughman RP, Barney JB, O'Hare L, Lower EE—Respiratory Medicine, 2016
Disclosure statement: Funding to support this study was provided by Mallinckrodt Pharmaceuticals.
To analyze the use of Acthar Gel in patients who had an incomplete response to their current therapy because of progressive, symptomatic disease, and despite immunosuppressive therapy and/or excessive toxicity with current treatment
CNS=central nervous system; FVC=forced vital capacity; PET=positron emission tomography.
Primary target organ response after ≥3 months of Acthar Gel treatment (n=29)1
FVC=forced vital capacity.
*Reduced inflammation, >10% improvement in FVC, >50% reduction in use of topical glucocorticoids, or improvement in other organ abnormalities.
†No clinically significant change in target organ, but reduction in dosage of glucocorticoids.
‡Worsening of target organ when prednisone was reduced and patient had to be maintained on initial or higher dose of glucocorticoids.
CNS=central nervous system.
ADVERSE EVENTS
18 OF 47 PATIENTS DISCONTINUED TREATMENT DUE TO:
Start the referral process for your appropriate patients
Acthar® Gel is indicated for:
Contraindications
Acthar is contraindicated:
Warnings and Precautions
Adverse Reactions
Pregnancy
Please see full Prescribing Information for additional Important Safety Information.
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References: